/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
MONTREAL, Feb. 2, 2024 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) ("Valeo"), a Canadian pharmaceutical company, announced today that it has entered into an amendment (the "Amendment") of its 7-year Commercialization and Supply Agreement (the "Commercialization and Supply Agreement") of XIIDRA® and SIMBRINZA® originally entered into with Novartis Pharmaceuticals Canada Inc. ("Novartis") in July 2022. For sake of clarity SIMBRINZA® is a registered trademark of Novartis AG while XIIDRA® is a registered trademark of Bausch and Lomb. The use of both trademarks has been authorized only in the context of this press release.
Read more at newswire.ca